AHA 2024

At the American Heart Association Scientific Sessions 2024 (November 15-18), leading lipid specialists presented latest analyses from the PALISADE, MUIR and SHASTA Open Label Extension, and REDUCE-IT studies together with new insights into the role of apoC in aortic stenosis.   Read the reports: Reporting by Jenny Bryan 

Sustained reductions in TG and other lipids have been reported with plozasiran in the Phase 3 PALISADE trial, and in the MUIR and SHASTA-2 open label extension (OLE) study.1,2

Icosapent ethyl (IPE) reduces cardiovascular (CV) risk in statin-treated patients with CV disease whether or not they have coronary artery disease (CAD). These are the findings from the latest analysis of data from the REDUCE-IT trial (REDUCE-IT CAD).

Designers of future trials of TG-lowering therapy may want to consider enrolling patients with a wider range of TG levels than in previous studies if there is no prior history of pancreatitis. This is the advice of Professor Paul Ridker (Brigham and Women’s Hospital, Boston, USA) and colleagues in the light of an analysis of […]

The ω-3 carboxylic acid (CA) formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) used in the STRENGTH trial significantly reduced major adverse cardiovascular events (MACE) compared with corn oil in Asian but not in non-Asian patients at high cardiovascular (CV) risk.1 This may help to explain why the EPA/DHA combination did not significantly change […]

Results of a Mendelian randomisation (MR) study support APOC3 inhibition as a therapeutic option for aortic stenosis (AS) treatment. Analysis of TG level and AS data from genome-wide association studies confirmed that the genetically predicted TG levels were significantly associated with increased risk of AS (IVW: OR 1.28 per standard deviation increase in genetically predicted […]